Crescita Therapeutics Inc. (TSX:CTX)
| Market Cap | 14.15M +34.1% |
| Revenue (ttm) | 23.22M +28.1% |
| Net Income | -320.00K |
| EPS | -0.02 |
| Shares Out | 18.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,782 |
| Average Volume | 16,645 |
| Open | 0.7700 |
| Previous Close | 0.7600 |
| Day's Range | 0.7600 - 0.7700 |
| 52-Week Range | 0.4000 - 0.7700 |
| Beta | -0.15 |
| RSI | 81.52 |
| Earnings Date | May 22, 2026 |
About Crescita Therapeutics
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary drug delivery platforms, which include Multiplexed Molecular Penetration Enhancers and DuraPee that supports the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. The c... [Read more]
Full Company ProfileFinancial Performance
In 2025, Crescita Therapeutics's revenue was 21.12 million, an increase of 7.85% compared to the previous year's 19.58 million. Losses were -92,000, -96.65% less than in 2024.
Financial StatementsNews
Crescita Therapeutics Inc. Obtains Final Order Approving Plan of Arrangement
LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) is pleased to announce that it has obtained a final court order from the Ontario S...
Crescita Obtains Shareholder Approval To Be Acquired By ClinActiv Holdings
LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) today announced that at its special meeting (the “Meeting”) of shareholders (the “...
Crescita Reports First Quarter 2026 Results
LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, tod...
Crescita Therapeutics Earnings release: Q1 2026
Crescita Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Crescita Therapeutics Quarterly report: Q1 2026
Crescita Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Crescita Announces Filing and Mailing of Special Meeting Materials and Receipt of Interim Order in respect of Arrangement with ClinActiv Holdings
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) announced today that it has filed and mailed the management information circular (...
Crescita Reports Q4 and Fiscal 2025 Results
LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, tod...
Crescita Therapeutics Earnings release: Q4 2025
Crescita Therapeutics released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Crescita Announces Definitive Agreement to Be Acquired by ClinActiv Holdings in an All-Cash Transaction at a Significant Premium
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) today announced that it has entered into a definitive arrangement agreement (the “...
Crescita Reports Third Quarter 2025 Results
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, tod...
Crescita Therapeutics Earnings release: Q3 2025
Crescita Therapeutics released its Q3 2025 earnings on November 4, 2025, summarizing the period's financial results.
Crescita Reports Second Quarter 2025 Results
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, tod...
Crescita Therapeutics Earnings release: Q2 2025
Crescita Therapeutics released its Q2 2025 earnings on August 5, 2025, summarizing the period's financial results.
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, tod...
Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis®
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with...
Crescita Reports First Quarter 2025 Results
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, tod...
Crescita Therapeutics Earnings release: Q1 2025
Crescita Therapeutics released its Q1 2025 earnings on May 14, 2025, summarizing the period's financial results.
Crescita Therapeutics Earnings release: Q4 2024
Crescita Therapeutics released its Q4 2024 earnings on March 17, 2025, summarizing the period's financial results.
Crescita Reports Third Quarter 2024 Results
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, tod...
Crescita Therapeutics Earnings release: Q3 2024
Crescita Therapeutics released its Q3 2024 earnings on November 5, 2024, summarizing the period's financial results.
Crescita Therapeutics Transcript: Planet MicroCap Showcase: VANCOUVER 2024
A fully integrated dermatology company highlighted its diverse product portfolio, strong cash position, and recent acquisition of Aquafolia. Growth strategies focus on expanding commercial reach, securing long-term manufacturing contracts, and finding a new U.S. partner for Pliaglis.
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, tod...
Crescita to Present & Participate in 1x1 Meetings at the Planet MicroCap Showcase: VANCOUVER 2024 in Association with Small Cap Discoveries on Thursday, September 26, 2024
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, tod...
Crescita Reports Second Quarter 2024 Results
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, tod...
Crescita Therapeutics Earnings release: Q2 2024
Crescita Therapeutics released its Q2 2024 earnings on August 5, 2024, summarizing the period's financial results.